JPWO2019183499A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019183499A5 JPWO2019183499A5 JP2020550713A JP2020550713A JPWO2019183499A5 JP WO2019183499 A5 JPWO2019183499 A5 JP WO2019183499A5 JP 2020550713 A JP2020550713 A JP 2020550713A JP 2020550713 A JP2020550713 A JP 2020550713A JP WO2019183499 A5 JPWO2019183499 A5 JP WO2019183499A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- cdr2
- heavy chain
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 181
- 239000000427 antigen Substances 0.000 claims description 161
- 102000036639 antigens Human genes 0.000 claims description 161
- 108091007433 antigens Proteins 0.000 claims description 161
- 238000000034 method Methods 0.000 claims description 61
- 210000004027 cell Anatomy 0.000 claims description 49
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 41
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 claims description 36
- 102000056374 human MYDGF Human genes 0.000 claims description 36
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 102000004127 Cytokines Human genes 0.000 claims description 13
- 108090000695 Cytokines Proteins 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 13
- 230000004936 stimulating effect Effects 0.000 claims description 12
- 230000028993 immune response Effects 0.000 claims description 11
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 10
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 10
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 9
- 230000028327 secretion Effects 0.000 claims description 9
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 8
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 8
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 8
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 8
- 108010044012 STAT1 Transcription Factor Proteins 0.000 claims description 7
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 7
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 claims description 7
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 230000026731 phosphorylation Effects 0.000 claims description 7
- 238000006366 phosphorylation reaction Methods 0.000 claims description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 5
- 210000002865 immune cell Anatomy 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 101150106931 IFNG gene Proteins 0.000 claims description 3
- 108090001005 Interleukin-6 Proteins 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 102000013691 Interleukin-17 Human genes 0.000 claims description 2
- 108050003558 Interleukin-17 Proteins 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 description 13
- 229940124597 therapeutic agent Drugs 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 12
- 238000001514 detection method Methods 0.000 description 9
- 101000852964 Homo sapiens Interleukin-27 subunit beta Proteins 0.000 description 5
- 102100036712 Interleukin-27 subunit beta Human genes 0.000 description 5
- 208000006265 Renal cell carcinoma Diseases 0.000 description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 4
- 229960003301 nivolumab Drugs 0.000 description 4
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 229950002916 avelumab Drugs 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 2
- 101001102797 Homo sapiens Transmembrane protein PVRIG Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 2
- 102000017578 LAG3 Human genes 0.000 description 2
- 101150030213 Lag3 gene Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 239000012271 PD-L1 inhibitor Substances 0.000 description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 2
- 102100039630 Transmembrane protein PVRIG Human genes 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229960003982 apatinib Drugs 0.000 description 2
- 229960003852 atezolizumab Drugs 0.000 description 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960005167 everolimus Drugs 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 description 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 2
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 229960002633 ramucirumab Drugs 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 1
- SPMVMDHWKHCIDT-UHFFFAOYSA-N 1-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-3-(5-methyl-3-isoxazolyl)urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC=1C=C(C)ON=1 SPMVMDHWKHCIDT-UHFFFAOYSA-N 0.000 description 1
- MAUCONCHVWBMHK-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)-oxomethyl]phenoxy]ethyl]-2-benzofurancarboxamide Chemical compound O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MAUCONCHVWBMHK-UHFFFAOYSA-N 0.000 description 1
- MLDQJTXFUGDVEO-FIBGUPNXSA-N 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-(trideuteriomethyl)pyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC([2H])([2H])[2H])=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-FIBGUPNXSA-N 0.000 description 1
- 108010075480 ADI PEG20 Proteins 0.000 description 1
- 229940125565 BMS-986016 Drugs 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 description 1
- 206010062878 Gastrooesophageal cancer Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- 229940125563 LAG3 inhibitor Drugs 0.000 description 1
- UCEQXRCJXIVODC-PMACEKPBSA-N LSM-1131 Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-PMACEKPBSA-N 0.000 description 1
- 101100018698 Mus musculus Il27 gene Proteins 0.000 description 1
- 108700031757 NKTR-214 Proteins 0.000 description 1
- 229940124060 PD-1 antagonist Drugs 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 229940044665 STING agonist Drugs 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229940125567 TSR-033 Drugs 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 229950008805 abexinostat Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229940042992 afinitor Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- 229940121413 bempegaldesleukin Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940036033 cabometyx Drugs 0.000 description 1
- 229960001292 cabozantinib Drugs 0.000 description 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
- HFCFMRYTXDINDK-WNQIDUERSA-N cabozantinib malate Chemical compound OC(=O)[C@@H](O)CC(O)=O.C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 HFCFMRYTXDINDK-WNQIDUERSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229950006370 epacadostat Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940125449 fotivda Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000006974 gastroesophageal cancer Diseases 0.000 description 1
- 229940121569 ieramilimab Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 229940005319 inlyta Drugs 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 1
- 229940064847 lenvima Drugs 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229940124303 multikinase inhibitor Drugs 0.000 description 1
- FYJROXRIVQPKRY-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 FYJROXRIVQPKRY-UHFFFAOYSA-N 0.000 description 1
- 229940080607 nexavar Drugs 0.000 description 1
- 229960004378 nintedanib Drugs 0.000 description 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 229950007213 spartalizumab Drugs 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940066453 tecentriq Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229950005976 tivantinib Drugs 0.000 description 1
- 229940100411 torisel Drugs 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940069559 votrient Drugs 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023078028A JP7742377B2 (ja) | 2018-03-22 | 2023-05-10 | 抗ｉｌ－２７抗体及びその使用 |
| JP2024185935A JP7766162B2 (ja) | 2018-03-22 | 2024-10-22 | 抗ｉｌ－２７抗体及びその使用 |
| JP2025181096A JP2026016604A (ja) | 2018-03-22 | 2025-10-27 | 抗ｉｌ－２７抗体及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862646496P | 2018-03-22 | 2018-03-22 | |
| US62/646,496 | 2018-03-22 | ||
| PCT/US2019/023625 WO2019183499A1 (en) | 2018-03-22 | 2019-03-22 | Anti-il-27 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023078028A Division JP7742377B2 (ja) | 2018-03-22 | 2023-05-10 | 抗ｉｌ－２７抗体及びその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021518138A JP2021518138A (ja) | 2021-08-02 |
| JPWO2019183499A5 true JPWO2019183499A5 (https=) | 2022-03-30 |
| JP2021518138A5 JP2021518138A5 (https=) | 2022-03-30 |
| JP7328983B2 JP7328983B2 (ja) | 2023-08-17 |
Family
ID=67987990
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020550713A Active JP7328983B2 (ja) | 2018-03-22 | 2019-03-22 | 抗ｉｌ－２７抗体及びその使用 |
| JP2023078028A Active JP7742377B2 (ja) | 2018-03-22 | 2023-05-10 | 抗ｉｌ－２７抗体及びその使用 |
| JP2024185935A Active JP7766162B2 (ja) | 2018-03-22 | 2024-10-22 | 抗ｉｌ－２７抗体及びその使用 |
| JP2025181096A Pending JP2026016604A (ja) | 2018-03-22 | 2025-10-27 | 抗ｉｌ－２７抗体及びその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023078028A Active JP7742377B2 (ja) | 2018-03-22 | 2023-05-10 | 抗ｉｌ－２７抗体及びその使用 |
| JP2024185935A Active JP7766162B2 (ja) | 2018-03-22 | 2024-10-22 | 抗ｉｌ－２７抗体及びその使用 |
| JP2025181096A Pending JP2026016604A (ja) | 2018-03-22 | 2025-10-27 | 抗ｉｌ－２７抗体及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11332524B2 (https=) |
| EP (1) | EP3768317A4 (https=) |
| JP (4) | JP7328983B2 (https=) |
| KR (2) | KR102879521B1 (https=) |
| CN (3) | CN120463807A (https=) |
| AU (1) | AU2019239324A1 (https=) |
| BR (1) | BR112020018918A2 (https=) |
| CA (1) | CA3093740A1 (https=) |
| IL (2) | IL326896A (https=) |
| MA (1) | MA52094A (https=) |
| MX (2) | MX2020009879A (https=) |
| SG (1) | SG11202008707YA (https=) |
| WO (1) | WO2019183499A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120463807A (zh) | 2018-03-22 | 2025-08-12 | 表面肿瘤学有限责任公司 | 抗il-27抗体及其用途 |
| BR112021011393A2 (pt) * | 2018-12-13 | 2021-08-31 | Surface Oncology, Inc. | Anticorpos anti-il-27 e usos dos mesmos |
| MX2022003719A (es) * | 2019-09-25 | 2022-04-26 | Surface Oncology Inc | Anticuerpos anti-il-27 y sus usos. |
| US12240897B2 (en) * | 2020-09-22 | 2025-03-04 | Institute For Cancer Research | Treatment of non-alcoholic steatohepatitis (NASH) with IL-27 antibody |
| US12577299B2 (en) * | 2021-05-07 | 2026-03-17 | Surface Oncology, LLC | Anti-IL-27 antibodies and uses thereof |
| WO2023230116A1 (en) * | 2022-05-25 | 2023-11-30 | Surface Oncology, Inc. | Use of anti-il-27 antibodies |
| WO2023230128A1 (en) * | 2022-05-25 | 2023-11-30 | Surface Oncology, Inc. | Use of anti-il-27 antibodies |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| DK0580737T3 (da) | 1991-04-10 | 2004-11-01 | Scripps Research Inst | Heterodimere receptorbiblioteker ved anvendelse af phagemider |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| WO1993015722A1 (en) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| AU701578B2 (en) | 1992-08-21 | 1999-02-04 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
| PT1231268E (pt) | 1994-01-31 | 2005-11-30 | Univ Boston | Bancos de anticorpos policlonais |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| US6001329A (en) | 1996-05-06 | 1999-12-14 | Uab Research Foundation | Radiolabeled fusion toxins for cancer therapy |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6995259B1 (en) | 1998-10-23 | 2006-02-07 | Sirna Therapeutics, Inc. | Method for the chemical synthesis of oligonucleotides |
| US7148330B2 (en) | 1999-07-30 | 2006-12-12 | Schering Corporation | Binding compounds for IL-27 |
| CA2443862A1 (en) * | 2001-04-17 | 2002-10-24 | Peizhi Luo | Structure-based construction of human antibody library |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| CA2555421A1 (en) * | 2004-02-17 | 2005-09-01 | Schering Corporation | Agonists and antagonists of p28 ebi3 and wsx/tccr for treating immune disorders |
| CN101001872A (zh) * | 2004-04-16 | 2007-07-18 | 宏观基因有限公司 | FcγRIIB－特异性抗体及其使用方法 |
| US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| KR20130108481A (ko) | 2005-08-19 | 2013-10-02 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| EP1987837A1 (en) | 2007-05-02 | 2008-11-05 | Technische Universität Dresden Medizinische Fakultät Carl Gustav Carus | Pharmaceutical composition for increasing insulin secretion from pancreatic ß-cells |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US8691730B2 (en) | 2007-09-14 | 2014-04-08 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2011133931A1 (en) * | 2010-04-22 | 2011-10-27 | Genentech, Inc. | Use of il-27 antagonists for treating inflammatory bowel disease |
| WO2011140151A1 (en) | 2010-05-04 | 2011-11-10 | Dyax Corp. | Antibodies against epidermal growth factor receptor (egfr) |
| DK2593594T3 (en) | 2010-07-16 | 2017-12-11 | Adimab Llc | ANTIBODY LIBRARIES |
| AU2012205384B2 (en) | 2011-01-14 | 2015-09-10 | Five Prime Therapeutics, Inc. | IL-27 antagonists for treating inflammatory diseases |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| US20150284459A1 (en) | 2012-10-31 | 2015-10-08 | The Brigham And Women's Hospital, Inc. | Methods for modulating immune responses during chronic immune conditions by targeting il-27 induced pathways |
| BR112016015140A2 (pt) | 2013-12-30 | 2018-01-23 | Epimab Biotherapeutics Inc. | imunoglobulina com fabs in-tandem e usos das mesmas |
| US10092645B2 (en) | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| TWI695011B (zh) * | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗ｈｅｒ２表位之單株抗體及其使用之方法 |
| EP3916017A1 (en) | 2014-12-22 | 2021-12-01 | PD-1 Acquisition Group, LLC | Anti-pd-1 antibodies |
| WO2019024979A1 (en) | 2017-07-31 | 2019-02-07 | Institute For Research In Biomedicine | FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION |
| CN120463807A (zh) | 2018-03-22 | 2025-08-12 | 表面肿瘤学有限责任公司 | 抗il-27抗体及其用途 |
-
2019
- 2019-03-22 CN CN202510109584.4A patent/CN120463807A/zh active Pending
- 2019-03-22 KR KR1020207030240A patent/KR102879521B1/ko active Active
- 2019-03-22 CN CN202510101203.8A patent/CN120173101A/zh active Pending
- 2019-03-22 JP JP2020550713A patent/JP7328983B2/ja active Active
- 2019-03-22 WO PCT/US2019/023625 patent/WO2019183499A1/en not_active Ceased
- 2019-03-22 IL IL326896A patent/IL326896A/en unknown
- 2019-03-22 AU AU2019239324A patent/AU2019239324A1/en active Pending
- 2019-03-22 BR BR112020018918-9A patent/BR112020018918A2/pt unknown
- 2019-03-22 MX MX2020009879A patent/MX2020009879A/es unknown
- 2019-03-22 EP EP19772189.7A patent/EP3768317A4/en active Pending
- 2019-03-22 KR KR1020257036085A patent/KR20250160366A/ko active Pending
- 2019-03-22 CN CN201980027625.8A patent/CN112512571B/zh active Active
- 2019-03-22 SG SG11202008707YA patent/SG11202008707YA/en unknown
- 2019-03-22 MA MA052094A patent/MA52094A/fr unknown
- 2019-03-22 CA CA3093740A patent/CA3093740A1/en active Pending
- 2019-03-22 IL IL277330A patent/IL277330B1/en unknown
- 2019-03-22 US US16/362,457 patent/US11332524B2/en active Active
-
2020
- 2020-09-22 MX MX2025003476A patent/MX2025003476A/es unknown
-
2022
- 2022-04-06 US US17/714,942 patent/US20230042258A1/en active Pending
-
2023
- 2023-05-10 JP JP2023078028A patent/JP7742377B2/ja active Active
-
2024
- 2024-10-22 JP JP2024185935A patent/JP7766162B2/ja active Active
-
2025
- 2025-01-17 US US19/029,833 patent/US20250154244A1/en active Pending
- 2025-10-27 JP JP2025181096A patent/JP2026016604A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021518138A5 (https=) | ||
| CN106573977B (zh) | 针对ceacam1的人源化抗体 | |
| KR102333658B1 (ko) | 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체 | |
| EP3604338A1 (en) | Anti-ox40 antibody and use thereof | |
| CN108623685A (zh) | 抗ox40抗体及其用途 | |
| KR20170068458A (ko) | 항-ｎｋｇ2ａ 항체를 사용한 치료 요법 | |
| US20230096030A1 (en) | Bispecific antibodies against cd9 and cd7 | |
| TW202227132A (zh) | 使用抗ｐｄ－１抗體與抗ｃｔｌａ－４抗體之組合以治療肺癌 | |
| KR20170010764A (ko) | 신규한 항-ｒｎｆ43 항체 및 사용 방법 | |
| WO2019140150A1 (en) | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer | |
| AU2020254100B2 (en) | Anti-CD73, anti-PD-L1 antibodies and chemotherapy for treating tumors | |
| CN112203691A (zh) | 癌症的治疗 | |
| CN113677707A (zh) | 用于在治疗癌症中增强效力的il-4/il-13途径抑制剂 | |
| JP2023548051A (ja) | 肺がんのためのｌａｇ－３アンタゴニスト療法 | |
| CN114340679A (zh) | 用于治疗对pd-1/pd-l1信号传导抑制剂无应答的癌症的方法和药物 | |
| JP2024012300A (ja) | 医薬併用 | |
| WO2017205213A1 (en) | Combination therapy of abemaciclib and immune checkpoint modulators for use in the treatment of cancer | |
| KR20240135661A (ko) | 간세포성 암종에 대한 조합 요법 | |
| JPWO2019183499A5 (https=) | ||
| CN118176214A (zh) | 血液癌症的lag-3拮抗剂疗法 | |
| JPWO2020123011A5 (https=) | ||
| CN113226369A (zh) | 给药 | |
| CN120731228A (zh) | 肺癌的组合疗法 | |
| JP2024511106A (ja) | Ｐｄ－１阻害剤を投与することにより免疫抑制または免疫不全患者におけるがんを処置する方法 | |
| JP2024511977A (ja) | 抗ｉｌｔ３抗体によるがんの治療方法 |